KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
Pasi A. Jänne, Igor I. Rybkin, Alexander I. Spira, Gregory J. Riely, K. Papadopoulos, Joshua K. Sabari, Melissa L. Johnson, Rebecca S. Heist, Lyudmila Bazhenova, Minal Barve, J.M. Pacheco, Ticiana Leal, Karen Velastegui, Crystal Cornelius, Peter Olson, James G. Christensen, Thian Kheoh, Richard C. Chao, S.‐H.I. Ou
Topics & Concepts
KRASCancer researchTolerabilityMutationLung cancerAdenocarcinomaCancerOncogeneMedicineBiologyInternal medicineColorectal cancerCell cycleAdverse effectGeneticsGeneLung Cancer Treatments and MutationsCancer therapeutics and mechanismsProtein Kinase Regulation and GTPase Signaling